Xcorporeal Announces Presentation at the Roth Capital Partners 20th Annual Growth Stock Conference on February 19th, 2008
February 15 2008 - 8:30AM
Business Wire
Xcorporeal, Inc. (AMEX:XCR) announced today that Dan Goldberger,
Chief Executive Officer of Xcorporeal, will be presenting at the
Roth Capital Partners 20th Annual Growth Stock Conference on
Tuesday, February 19th, 2008 at 3:30 PM Pacific Time. The
conference will be held February 18-21 at the Ritz Carlton Laguna
Niguel in Southern California. The Company�s presentation will also
be webcast live and archived for future reference at
www.wsw.com/webcast/roth16/xcor/ and also available on the
Company�s website at www.xcorporeal.com. About Xcorporeal
Xcorporeal, Inc. is a medical device company developing an
innovative extra-corporeal platform technology that may be used in
devices to replace the function of various human organs. The
platform will lead to three initial products; the first, a device
for hospital Renal Replacement Therapy (RRT), another device for
home hemodialysis and the Wearable Artificial Kidney (WAK) for
continuous ambulatory hemodialysis. These devices will seek to
provide patients with improved, efficient and cost effective
therapy. The RRT markets represent multibillion dollar
opportunities. For the RRT market, Xcorporeal is developing a
portable, multifunctional renal replacement device that will offer
cost effective therapy for those patients suffering from Acute
Renal Failure (ARF) which causes a rapid decline in kidney
function. In the U.S., the disease affects more than 200,000
patients annually, with a mortality rate of 50%. The Xcorporeal
platform technology is a natural fit for the hospital market of
renal replacement therapy since the technology is designed to
provide cost-effective, continuous therapy. The projected 2008
market opportunity for the U.S. is approximately $1.1 billion. The
disposable market is expected to grow at 10% per year.
Hospital-based devices typically need to be replaced every five
years. The Company has completed its functional prototype of the
product, which is currently undergoing bench testing, and intends
to generate an initial filing with the Food and Drug Administration
(FDA), under a 510(k), during the fourth quarter of 2008.
Xcorporeal also plans to commercialize a home hemodialysis machine
for the End Stage Renal Disease (ESRD) market, which are patients
in which the kidneys cease to function. Xcorporeal's devices will
combine the best attributes of currently marketed home hemodialysis
machines to create hemodialysis devices which offer patients
convenient, durable and truly portable devices for home use. The
Company believes its machines will provide a cost-effective
alternative to current home treatment modalities, due to their
ability to offer hemodialysis without the need for large quantities
of dialysate fluid or purified water. The Company has completed its
functional prototype of the product, which is currently undergoing
bench testing, and intends to generate an initial filing with the
FDA, under a 510(k), during the second half of 2009. The WAK will
be a revolutionary device intended to enable patients with ESRD to
achieve a quality of life closer to that of healthy individuals.
The WAK has recently been featured in articles written by The Los
Angeles Times, The Lancet, Kidney International and various other
medical periodicals. Additional Company information may be found on
the Internet at: www.xcorporeal.com. Forward-Looking Statements
Except for statements of historical fact, the matters discussed in
this press release are forward looking and made pursuant to the
Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many
of which are beyond the company's control that may cause actual
results to differ materially from stated expectations. These risk
factors include, among others, limited operating history,
difficulty in developing, exploiting and protecting proprietary
technologies, intense competition and substantial regulation in the
medical device industry; and additional risks factors as discussed
in the reports filed by the company with the Securities and
Exchange Commission, which are available on its website at
http://www.sec.gov.
Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From Oct 2023 to Oct 2024